SESN Price TargetOn 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00.
Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment.
buying long term calls could be a strategy for this one. volatility is likely after they announce the second FDA submission.
SESN
SESN Sesen Bio Selloff | Buy the dip???SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support.
The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. (businesswire.com)
And they don`t have only one product in their pipeline.
Sesen Bio focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. (marketbeat.com)
On 8/11/2021 BlackRock Inc. reported 10,657,812 for a total of $49.24M +264.7% increase and an ownership in SESN of 6.150%
On 8/13/2021 Vanguard Group Inc. reported 8,503,982 for a total of $39.29M +18.2% increase and an ownership in SESN 4.339%
My price target is between 2.7 to 3.2usd.
I look forward to read your opinion
SESN Haven't Seen You In A WhileTook the chart all the way back out to 2015 to find some relevant levels and did a quick fib retracement. Aside from the 236 level being a key point of resistance, in 2015, the area around $5.20 presented an interesting area of high traffic. SESN managed to break through this briefly but as you'll see, it was fleeting after putting in the top that I used as the upper anchor. Heading into the end of the week, this area could be important to watch.
" SENS stock is another decent gainer of the day, pushing up by around 8% in afternoon trading. For some context, Senseonics is a producer of medical products that monitor metrics for those with diabetes. Its product line includes several CGM (continuous glucose monitoring) systems such as the Eversense and Eversense XL...These devices utilize a sensor inserted under the skin to track a patient’s glucose levels. It can then send this data to a smartphone which puts it ahead of the existing technology by quite a ways. At the beginning of this week, Senseonics announced its second-quarter 2021 financial results. In the report, the company posted revenue of around $3.3 million and managed to raise more than $50 million in proceeds through an at-the-market offering...In the U.S. and around the world, diabetes is a condition that affects millions. Because of this, Senseonics could have a sizable market opportunity moving forward. For these reasons, SENS stock could be worth keeping an eye on ."
Quote Source & Read more: Best Penny Stocks to Buy Now? 4 to Watch to Avoid Stock Market Crash
$sesn it was just starting the soaring journeythe chart and the board always are talking us for bright future
$sesn gap filled #sesen , only #long as i told you ..the gap should filled before fda approval for the new era and many ATH
pt is $12 short term and long term $20
the 2 gaps are the red rectangles .
V shape at our chart
ONLY LONG
lets start $sesn #sesenabove 10,21,50 MA and out of downtrend line before approval
$12 is coming veery soon
$sesn #sesen strong long for new era with vicineum stock to $12100% sure the approval and there we 28% short covering and the new era will start
my pt is 10-12 $$ short term
SE SE SESN DIT! I'll just say that there are a lot of stocks and cryptos reaching breaking points, and they will most likely all do the same thing. I'm seeing plenty of potential for most everything to break to the downside but the bullish charts look strong so that's what I'm going with. This SESN chart looks really good, but it's at the tipping point as we speak.
SESN to $5 or more by August. I like the stock.On the verge of FDA approval for a new product,
multiple analysts recently adjusting price targets to $6 plus.
In a market full of mania, a stock with good fundamentals may get overhyped especially about something as legitimate as FDA approval.
Who's not talking about SESN and ENZC right now???
If FDA approval falls through both stocks will suffer a lot, so be careful here and watch for the breakout off support lines before going hard.
The trend is your friend unil the end. Look for confirmations of your (or my) predictions, thats what TA is all about.
Hit me with a like, follow this chart, tell me your thoughts and give me a follow.
If you haven't upgraded yout TV account, use my link to upgrade.
Cheers, traders!!
Ideal SESN entry for 6-8 month investment timeline pending newsWhile it is historically (and notoriously if you're any kind of long in it already) a slow-moving biotech stock, when these sudden capitulation dips occur is when smart setups present themselves and the stock runs past previous support/resistance levels off pure momentum rallies from the lows in the large symmetrical triangle pattern. A potential run such as this would not only net big profit and provide the best support for safe entry, but also aligns with the timeline for their expected BLA approval from FDA for Vicinium. A breakout to the upside from this pattern alone, without positive news behind it and purely from a technician POV, should imply around a 300% upside (measuring the distance between the highest and lowest points in the triangle and adding it to the breakout point). I think the positive news just gets you there quicker with volume surge.
I will watch and see how the pattern develops over the next two weeks before deciding whether or not to open a long position. If the price action finds strong enough support along the trendline I think it's a solid setup for a long trade.
